

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Predicting the severity of disease progression in COVID-19 at the individual and population level: A mathematical model

Narendra Chirmule¹, Pradip Nair², Bela Desai³,

Ravindra Khare¹, Vivek Nerurkar⁴, Amitabh Gaur⁵,

¹ SymphonyTech Biologics, Philadelphia, Pennsylvania, USA; ² Biocon, Bangalore, Karnataka, India; ³ NanoCollect Biomedical, Inc., San Diego, California, USA, ⁴ Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA, ⁵ Innovative Assay Solutions LLC, San Diego, California, USA.

Address Correspondence to:

Narendra Chirmule at Narendra.Chirmule@symphonytech.com or

Amitabh Gaur at agaursd@gmail.com

Key words: innate, interferon, cytokine-storm, lymphopenia, neutralizing-antibodies, viral factors, modeling, prediction

18 Conflict of Interest Statement.

19 Narendra Chirmule and Ravindra Khare are employed by SymphonyTech Biologics Inc, and
20 own stock in the company; the opinions of Pradip Nair do not represent those of Biocon; Bela
21 Desai, Vivek Nerurkar and Amitabh Gaur do not have any conflict of interest.

22

23

24 **ABSTRACT**

25 The impact of COVID-19 disease on health and economy has been global, and the magnitude of
26 devastation is unparalleled in modern history. Any potential course of action to manage this
27 complex disease requires the systematic and efficient analysis of data that can delineate the
28 underlying pathogenesis. We have developed a mathematical model of disease progression to
29 predict the clinical outcome, utilizing a set of causal factors known to contribute to COVID-19
30 pathology such as age, comorbidities, and certain viral and immunological parameters. Viral load
31 and selected indicators of a dysfunctional immune response, such as cytokines IL-6 and IFN α ,
32 which contribute to the cytokine storm and fever, parameters of inflammation d-dimer and
33 ferritin, aberrations in lymphocyte number, lymphopenia, and neutralizing antibodies were
34 included for the analysis. The model provides a framework to unravel the multi-factorial
35 complexities of the immune response manifested in SARS-CoV-2 infected individuals. Further,
36 this model can be valuable to predict clinical outcome at an individual level, and to develop
37 strategies for allocating appropriate resources to mitigate severe cases at a population level.

38

39 INTRODUCTION

40 The COVID-19 pandemic caused by infection with SARS-CoV-2 was officially announced in
41 March 2020 by the CDC and WHO [1, 2]. As of this publication, more than 100 million
42 infections and over 2.6 million deaths have been reported worldwide. Majority of the subjects
43 have asymptomatic infections. The rate of fatality is disproportionately high in the elderly and
44 patients with comorbidities such as diabetes, cardiac disease, and kidney disease [3, 4]. The
45 consequences of the pandemic are fraught with potential loss of lives, social and economic
46 distress, and the uncertainty of disease progression because of variable individual pathogenesis.

47 A unique and dysregulated immune response has been shown to be a hallmark of
48 COVID-19 [5-9]. **Figure 1** schematically depicts the cascade of events that contribute to the
49 progression of disease. Mathematical models have been utilized by several investigators to
50 understand the mechanisms of disease pathogenesis, immune pathways involved and course of
51 viral infections [10, 11]. In this article, we have proposed a predictive model that utilizes the
52 levels of clinical and laboratory parameters to determine the severity of clinical outcomes
53 ranging from asymptomatic to mild, moderate, severe, and critical disease states. The proposed
54 model can be useful to predict clinical outcome at the individual-level and develop efficient and
55 effective treatment strategies to manage public health challenges at the population-level.

56 The questions the model attempts to answer are: i) At an individual level, what is the
57 probability of an individual infected with SARS-CoV-2, given the clinical signs and laboratory
58 values on various days, likely to progress to severe disease, and ii) At a population level, what
59 are the prioritized clinical and laboratory parameters that are most likely to contribute to
60 progression to severe disease. We have used a multiple regression based model to predict

61 severity of the outcome of COVID-19. To evaluate the combinatorics that are not observed in the
62 sample, we have applied resampling methods based on Monte Carlo simulation.

63

64 **METHODS**

65 **Development of a Simulated Dataset**

66 A simulated data set of 45 individual subjects was created with 15 subjects assumed to be
67 asymptomatic, 15 with moderate disease, and 15 with severe COVID-19 [12, 13]. The simulated
68 values for the viral and immune parameters were generated using data from clinical reports
69 published in the last year for each of the selected parameters. **Table 1** provides the ranges and
70 the related references for the values for all parameters and **Figure 2** shows the box-and-whisker
71 plots for the distribution of the values for each parameter.

72 **Data Modeling**

73 We have applied Multiple Linear Regression approach to the simulated data set for COVID-19
74 subjects generated and analyzed to understand the impact of each of the parameters on the
75 outcome of disease severity. We chose a multiple regression model since both, the outcomes and
76 predictors, were numeric. We used regression models to establish a predictive transfer function
77 and evaluated significance of results. In this model, the relationship between independent
78 variables ($\mathbf{x}_1, \mathbf{x}_2 \dots \mathbf{x}_n$) with dependent variable (\mathbf{y}) can be visualized by the equation, $\mathbf{y} = \mathbf{f}(\mathbf{x}_1,$
79 $\mathbf{x}_2 \dots \mathbf{x}_n)$. This is the transfer function that is derived through analysis. The validity of the model
80 was established using 'Goodness of Fit' and ANOVA. The statistical significance of the model
81 was tested by evaluating residuals and F Ratio in one-way ANOVA, based on the criteria of p

82 <0.05 and goodness-of-fit with Adj. RSq >90%. The assumption for this analysis was that each
83 of the parameters was independent. However, in cases where factual patient datasets will be
84 subjected to this type of analysis, there may be multi-co-linearity within the parameters that
85 should be rationalized using dimensionality reduction methods [14, 15].

86 Since the model may not exhibit multiple combination of parameters in the limited
87 dataset of 45 subjects, we have used resampling methods using Monte Carlo simulation to
88 achieve a better density of combinations. The simulation was applied for resampling of the
89 transfer function with 2000 runs, where a convergence was achieved after multiple runs. The
90 simulation was performed in order to understand the impact of possible parameter combinations
91 on clinical outcomes. Monte Carlo simulation uses random variates from selected range of values
92 to model the impact of progression of events leading to outcomes.

93 **Data analysis using training and testing data sets**

94 Model building involved partitioning the data set into ‘training’ and ‘testing’ sets. We
95 apportioned 70% of the data to train the model and used the remaining 30% to test the model,
96 using random selection algorithms. Following development of the model, we analyzed a set of
97 test data to compare predicted versus observed results to validate the model. The regression
98 model generated a prediction formula as follows:

$$\begin{aligned} 99 \quad \mathbf{Outcome} = & -36.898 - 0.020 \text{ AGE} + 0.894 \text{ COMORBID} - 0.048 \text{ Viral Load} - 0.004 \text{ IFN}\alpha + 0.444 \\ 100 \quad & \text{Fever} - 0.003 \text{ IL6} + 0.271 \text{ D-Dimer} + 0.000 \text{ Ferritin} - 0.000 \text{ Lymphocyte Count} - 0.037 \text{ O}_2 \\ 101 \quad & \text{saturation} - 2.57034\text{e-}006 \text{ NAB} \end{aligned}$$

102

103 The linear coefficients of the prediction equation determined the weights of each parameter to
104 predict the clinical outcome.

105 **Estimation of the coefficients of input parameters**

106 The modeling approach was based on utilizing clinical and laboratory parameters to fit the
107 regression models. Since direct comparison of regression coefficients was not necessary, and
108 interactions in factors were not considered on account of assumption of independence of factors,
109 we chose to leave the factor-data in the original scales.

110 **Rationale for the parameters included in the analysis**

111 The input parameters selected for this model, which requires cause (clinical and laboratory
112 parameters) and effect (clinical outcome) relationships, were based on the data reported in recent
113 scientific publications. **Figure 1** shows the schematic representation of the stage of disease
114 progression and parameters associated with the increasing severity of diseases. The following
115 parameters were chosen:

- 116 1. **Comorbidities:** Though the precise mechanism(s) of disease progression in patients with
117 comorbidities has yet to be elucidated, pre-existing conditions such as diabetes, cancer,
118 neurological, cardiac and lung and kidney disease have been reported to contribute towards
119 severity of COVID-19 [16, 17]. The simulated data for comorbidity was generated using
120 an arbitrary range of 1 to 4, where 1 represented a healthy individual and 4 represented an
121 individual with a severe co-morbidity.
- 122 2. **Age:** A range of 18 to 100 years was utilized for generating the mock data set. The
123 assumption used in generating the data was that disease progression was directly
124 proportional to age [17]. Reports of certain rare pathogenic conditions in children, e.g.,

125 Kawasaki disease [18, 19], have not been considered in the current model. Reports indicate
126 that majority of children infected with SARS-CoV-2 are asymptomatic [19].

127 3. **Viral load:** SARS-CoV-2 infects individuals through the nasopharyngeal pathway. This
128 infection is the cause of all subsequent effects. Viral load is measured by reverse-
129 transcriptase quantitative PCR (RT-qPCR), which detects viral RNA from nasopharyngeal
130 swabs [20]. The test relies on multiple cycles of RNA amplification to produce detectable
131 amount of RNA in the mixed nucleic acid sample, reflected in the Cycle-time (Ct) value,
132 which is defined as the number of cycles necessary to detect the virus. A Ct value of less
133 than 20 is considered a high viral load while a Ct value of 35 and higher indicates a lower
134 level or near absence of viral infection [20]. Viral load in patients is dependent on various
135 factors, including number of ACE2 and TMPRSS2 receptors [21, 22], comorbidities,
136 cytokines, number of viral particles at infection, and the overall immune health status of the
137 patients [23-26]. Viral loads have been demonstrated to have a direct correlation with
138 severity of disease and mortality in COVID-19 [27, 28].

139 4. **Cytokine Storm:** High viral loads evoke defensive mechanisms that can induce
140 inflammation leading to a dysregulated innate immune response that could result in a
141 cytokine storm characterized by fever-inducing levels of cytokines such as IL6, IFN α ,
142 IL1 β and CXCL-10 [27, 29-33]. CXCL-10, interestingly was also found to be indicative of
143 severe outcomes in patients affected by the SARS CoV1 outbreak in 2002 [34]. Cytokine
144 storm has been implicated in contributing to pulmonary immunopathology, leading to
145 severe clinical disease and mortality. In this model, we have included levels of IFN α and
146 IL6 obtained from the published data.

- 147 5. **Systemic Inflammation:** Laboratory based parameters indicating inflammation in the
148 serum, such as D-Dimer and Ferritin, have been shown to lead to a reduction in blood
149 oxygen saturation levels, reflecting inadequate oxygenation in the lungs [35, 36].
- 150 6. **Lymphopenia:** Viral infection can lead to marked lymphopenia that can affect both CD4+
151 and CD8+ T cells [3, 28, 36]. Lymphopenia, reflected by significantly reduced CD4 and
152 CD8 T cells in peripheral blood, is likely due to sequestration and cell death and reflected
153 by significantly reduced CD4 and CD8 T cells in peripheral blood, has been reported in
154 moderate and severe COVID-19 patients. In addition, antigen specific CD8 Cytotoxic T
155 lymphocyte (CTL) responses have been detected approximately a week following viral
156 infection, and the magnitude of the response was observed to have protective or damaging
157 effects [37].
- 158 7. **Neutralizing antibodies:** Neutralizing antibodies bind to specific surface receptors on
159 infectious agents such as viruses and toxins, reducing or eliminating their ability to exert
160 harmful effects on cells. SARS-CoV-2 infected individuals generate a robust and long-
161 lasting neutralizing antibody response, and plasma from convalescent COVID-19 patients
162 has been used for treatment of severe disease with some success [38, 39]. It has recently
163 been reported that neutralizing antibodies to SARS-CoV-2 can predict severity and
164 survival, with higher titers being associated with severe disease in some instances [40].
165 .

166 **RESULTS**

167 We evaluated multiple approaches to develop mathematical models using parameters that can
168 predict the progression of disease. Candidate parameters were selected from mechanistic
169 understanding of the process of pathogenesis of COVID-19 to evaluate their possible impact on
170 the clinical outcome. Regression models utilize data to build predictive models. Hypotheses are
171 examined and confirmed with pre-determined statistical confidence and inferential power. These
172 models incorporate all the experimental variability in the data set. Since the models contained
173 numeric factors and numeric ordinal outcomes, we utilized methods of Multiple Linear
174 Regression [41]. In this approach, we used the simulated data set from COVID-19 affected
175 subjects, organized, and analyzed it to understand the variability of each of the parameters.

176 **Regression modeling approach**

177 The data set was parsed into training and testing partitions using methods of randomization. The
178 validity of the model was based on goodness-of-fit of $R^2 > 90\%$ and ANOVA, [p value < 0.05]
179 and a consequent F Ratio (**Table 2a and 2b**). These statistical results confirmed acceptable
180 degree of predictability of the model.

181 Following this multiple-regression analysis, we conducted 2,000 bootstrap samplings using the
182 predicted coefficients and random variates from chosen intervals of parameters. The assumption
183 for this analysis was that each of the parameters were independent variables. The coefficients of
184 each parameter were determined by using multiple regression analyses, which is the multiplier to
185 the parameter value in a linear regression equation. The inclusion of all the variables in analysis
186 ensures their contribution to the model [41]. However, analysts applying this model in the future
187 may, at their judgment, evaluate statistical significance of regression coefficients. Parameters

188 that are not significant maybe excluded using step wise regression. In our analysis, results based
189 on training dataset predictors matched with those from the test dataset confirming an acceptable
190 degree of predictability of the model. We invite the readers of this article to contact us to analyze
191 the predictive potential of the model using their data.

192 **Monte Carlo simulation**

193 To determine the factors that contribute to the clinical outcome at the population level, Monte
194 Carlo simulation was performed on a sample set of laboratory and clinical parameters covering
195 the full range, from asymptomatic to severe disease, of outcomes (stages 1-7 [Figure 2]) [12, 13].
196 The histogram and cumulative data (**Figure 3a**) show the distribution of asymptomatic to severe
197 outcomes. The Tornado chart (**Figure 3b**) shows the sensitivity of parameter to the outcome in
198 the selected range.

199 **The predictive model**

200 Based on the correlation coefficient of the parameters and the outcome from the training data set,
201 we developed a model using the prediction equation. **Table 4** shows the process of predicting the
202 outcome. When the numerical values of the individual parameters for each patient are entered
203 into the columns, the model predicts the outcome. The validation of the model will require data
204 from patients and clinical trials. The goal of this exercise was to develop a model that can be
205 used to predict the outcome in a large number of patients.

206

207 **DISCUSSION**

208 We have evaluated multiple regression analysis for mathematically modeling the course of
209 COVID-19 to predict clinical outcome. The premise of this model is that quantitatively measured
210 clinical and laboratory parameters involved in the pathogenesis of disease progression can be
211 mathematically mapped to a multiple-regression model. COVID-19 is initiated by infection of
212 the subject with SARS-CoV-2 with subsequent replication in the epithelial cells of the lung. The
213 factors that contribute to the viral load include number of cells that express the ACE2 and other
214 receptors, and inflammatory cytokines. Comorbidities contribute towards a more serious disease
215 progression. Virus infection of antigen presenting cells, such as dendritic cells, macrophages, and
216 other cell types including endothelial cells, results in activation of biochemical signals, which
217 lead to secretion of a battery of cytokines that include IL1 β and IL-6. The viral infection as well
218 as inflammatory cytokines cause fever and an increase in serum inflammatory factors such as D-
219 Dimer and Ferritin. Induction of an inflammatory response contributes to reduction of the total
220 numbers of lymphocytes from circulation. The inflammation results in a loss of lung function
221 (e.g., reduction in blood-oxygen levels), cardiac function (blood pressure) and can culminate in
222 multi-organ failure.

223 Subjects with a normal immune response can generally mount an adequate innate and
224 adaptive response to the virus. These individuals clear the virus by generating adaptive T cell
225 responses and neutralizing antibodies. Subjects with comorbid conditions can have compromised
226 immune function which could result in dysfunctional activation of inflammatory responses,
227 leading to worse clinical outcomes.

228 Selection of the parameters that were included in the model building process was
229 influenced by their perceived significance from current research reports. This list of factors is by
230 no means complete and it is expected that in due course a more comprehensive list will emerge.
231 This report provides a basis for creating a tool, independent of the number and type of
232 parameters, that could find utility in predicting the disease outcome using those parameters.

233 **Viral Load.** Association of viral load and progression of diseases has been reported for several
234 viral infections [42-44]. Viral load in COVID-19 is measured by qRT-PCR of SARS-CoV-2
235 using primers for the spike gene [43]. The correlation of high viral load with severity of disease
236 progression has been extensively demonstrated. The systemic dissemination of the virus has been
237 associated with expression of the ACE2 receptor on endothelial cells [21]]. Comorbid conditions
238 could enhance the expression of receptors and enable distribution of virus, thereby enhancing the
239 viral load, which can result in progression of disease.

240 **IFN α .** The critical role of Type I interferons in innate and adaptive immunity, leading to both
241 protective and pathogenic responses, has been reported in the case of several viral and bacterial
242 infections [45]. SARS-CoV-2 infection has been shown to result in a diverse range of effects on
243 Type I immune responses. Most patients elicit a strong IFN α response along with a battery of
244 inflammatory cytokines, some of which progress to a cytokine storm [46, 47]. Specific blocking
245 of the type I mediated signal transduction by various proteins of SARS-CoV-2 has been
246 demonstrated [48]. A remarkably high proportion of male subjects experiencing severe or critical
247 COVID-19 disease expressed an inability to produce sufficient levels of IFN α due to various
248 types of errors in the IFN genes. Curiously, majority of the male subjects possessed circulating
249 IFN α autoantibodies that had the ability to neutralize the endogenously produced cytokine,

250 thereby effectively reducing the available IFN α . The discovery of these two mechanisms for
251 lowering IFN α levels underscores its relevance in controlling the progression of disease in
252 individuals infected with the SARS-CoV-2 [49].

253 **D-Dimer.** D-Dimer is routinely measured in clinical situations because its levels correlate with
254 serious underlying conditions including venous thromboembolism, cancer and sepsis [48]. In the
255 case of COVID-19 patients, introduction of the virus brings about infection-induced
256 inflammatory alterations leading to coagulopathy. Lungs being the target of SARS-CoV-2, acute
257 injury to the lung as well as multi organ failure have been caused by the virus-induced cascade of
258 the inflammatory pathway. In an early study on 41 COVID-19 patients, those with severe disease
259 had higher levels of D-Dimer along with high levels of IL-8, TNF α and IL-2R [31]. Male
260 patients were found to have higher levels of IL-6, IL-2R, Ferritin and other markers of
261 inflammation compared to female. High levels of IL-6 showed a statistically significant
262 correlation with severe disease in a retrospective study as well [27]. One can hypothesize that
263 such patients would likely benefit from anticoagulation therapy.

264 **Ferritin.** A high level of ferritin, measure of stored iron, was found to be associated with severe
265 disease in COVID-19 patients and was linked to high fatality rates in a 72 patient prospective
266 study [33, 50, 51]. In another study on 39 patients, those with mild COVID-19 symptoms had
267 lower levels of ferritin while those with moderate or severe symptoms expressed higher levels of
268 ferritin [50].

269 **Lymphopenia.** Loss of lymphocytes after viral infections has been associated with severe
270 disease. The mechanisms involved in lymphodepletion can be implicated to be due to cell
271 death, cytokine storm and/or redistribution of lymphocyte populations [3, 33, 37]. In this model,

272 we have utilized lymphopenia as a measure of severity of disease progression. Loss of immune
273 function could result in several potential mechanisms of pathogenesis including autoimmunity,
274 hyperactivation, increased susceptibility to infections and organ dysfunction.

275
276 **Neutralizing Antibodies.** Induction of neutralizing antibodies directed to the receptor-binding
277 domain of the spike protein is critical for restricting entry of the virus into the cells and has been
278 one of the central tenets of a protective immune response. In this model, we have used a range of
279 IgG titers to spike protein for the simulated data set [52]. However, the role of neutralizing
280 antibodies induced in a large proportion of subjects following natural infection is still being
281 studied [53]. Some subjects do not elicit strong antibody responses. Sub-optimal levels of
282 antibodies may catalyze generation of virus mutants [54]. Neutralizing antibodies to the virus
283 have generally not correlated with reduced severity of disease in the primary infection. In
284 addition, it will be interesting to decipher the role of pre-existing antibodies reported recently in
285 the modulation of disease and its impact on vaccination regimens. Thus, the mechanisms
286 involved in the induction of antibodies, the repertoire and diversity of responses, and effects on
287 protection versus progression, remains to be clearly established.

288 The predictive model can have multiple applications, such as forecasting the percentage
289 of the population that will progress to severe disease in each geography, enabling logistics
290 planning for hospital beds, health care providers and personal-protective safety equipment.
291 Analysis of the coefficient of correlations of parameters with outcome of disease may provide
292 clues to a better understanding of the mechanism of action of disease pathogenesis. The model
293 can predict the probability of disease progression at an individual level, based on parameter data,
294 and can be used to understand the effect and impact of therapeutic interventions. The predictive

295 model can be utilized to analyze large amounts of data to develop algorithms for personalized
296 treatment regimens.

297 In summary, we have developed a probabilistic model that can be utilized to predict progression
298 of disease following infection with SARS-CoV-2. This model was developed using simulated
299 data based on published levels of COVID-19 related clinical and laboratory parameters and
300 provides an approach to predicting the outcome of disease. Validation of the model will require
301 existing data and the clinical outcomes of patients. Prediction of disease progression can be
302 highly valuable at an individual as well as population level.

303

304 **TABLES LEGENDS:**

305 **Table 1. Ranges of values for the parameters used for developing the simulated dataset for**
306 **the mathematical model.** The range of comorbidities was assigned arbitrary nominal value
307 between 1 to 4, with 1 being healthy, and 4 having multiple health-conditions (e.g., diabetes,
308 cancer etc.). The age ranges in the model were 18-100 years.

309 **Table 2A. Statistical analysis of coefficients for each parameter based on the multiple**
310 **regression analysis.** The Table shows the regression statistics. The statistical terms are: DF
311 (degrees of freedom); SeqSS (Sequential Sum Square); AdjSS (Adjusted Sum Square), AdjMS
312 (Adjusted Mean Squares), F ratio, p value.

313 **Table 2B. Coefficient and standard error for parameters.** The coefficients for each
314 parameter were determined by using multiple regression analyses, which is the multiplier to the
315 parameter value in a linear regression equation. The values of the coefficients of each of the
316 parameters are shown using ANOVA. The table shows the standard error, t and p values. The p
317 value denotes statistical significance to the outcome.

318 **Table 3. The Ranges for the Monte Carlo Simulation.**

319

320 **Table 4. The Prediction of outcome based on observed and predicted values.** The values of
321 the parameters for each of the seven subjects are entered in columns, upon running of the model.
322 The predicted values are calculated in numerical values in a range of 1-7, with 1 being
323 asymptomatic, and 7 most severe.

324

325 **FIGURE LEGENDS:**

326 **Figure 1. Schematic representation of the progression of disease.** The width of the triangles
327 denotes increase in levels of viral load (purple), cytokine storm (blue), and anti-inflammatory
328 symptoms (green); blue arrows denote T and B cell responses.

329 **Figure 2. Box-and-whisker plots of the simulated data.** The figures show the visual
330 representation of the summary, which includes median (Q2/50th percentile); first quartile (Q1/25th
331 percentile); third quartile (Q3/75th percentile); interquartile range in whiskers, maximum and
332 outliers.

333 **Figure 3a. Histogram from Monte Carlo Simulation.** 2,000 bootstrap samplings were
334 generated using the predicted coefficients from the linear regression analysis, from the intervals
335 of parameters. The minimum and maximum values for each of the parameters was set to the
336 levels. The distribution of the severity of outcome is in this frequency histogram. The values on
337 the x axis denote the disease severity, and y axis denote frequency of the population in each level
338 of clinical outcome.

339 **Figure 3b. The Tornado Chart.** The tornado chart shows the influence of each of the
340 parameters on the outcome. The positive values correlate positively towards the severity of
341 disease, and negative values towards asymptomatic disease.

342

343

344 **ACKNOWLEDGEMENTS**

345 VRN is partly supported by a grant (P30GM114737) from the Centers of Biomedical Research
346 Excellence, National Institute of General Medicine, National Institutes of Health.

347

348

349

350 **REFERENCES**

351

352 1. CDC. Coronavirus 2020 [31 October, 2020]. Available from:

353 <https://www.cdc.gov/coronavirus/2019-ncov/index.html>.

354 2. WHO. Coronavirus 2020 [31 October, 2020]. Available from: <https://covid19.who.int/>.

355 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected

356 with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. Epub

357 2020/01/28. doi: 10.1016/s0140-6736(20)30183-5. PubMed PMID: 31986264; PubMed Central

358 PMCID: PMC7159299.

359 4. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of

360 asymptomatic and symptomatic patients with mild COVID-19. *Clin Microbiol Infect*. 2020.

361 Epub 2020/05/04. doi: 10.1016/j.cmi.2020.04.040. PubMed PMID: 32360780.

362 5. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, et

363 al. Comprehensive mapping of immune perturbations associated with severe COVID-19. *Sci*

364 *Immunol*. 2020;5(49). Epub 2020/07/17. doi: 10.1126/sciimmunol.abd7114. PubMed PMID:

365 32669287; PubMed Central PMCID: PMC7402634.

366 6. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, et

367 al. Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection. *bioRxiv*. 2020.

368 Epub 2020/06/09. doi: 10.1101/2020.05.18.101717. PubMed PMID: 32511394; PubMed Central

369 PMCID: PMC7263541.

370 7. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of

371 COVID-19: Current State of the Science. *Immunity*. 2020. Epub 2020/06/09. doi:

372 10.1016/j.immuni.2020.05.002. PubMed PMID: 32505227; PubMed Central PMCID:

373 PMCPMC7200337 Sciences, Primevax, Novartis, Array BioPharma, Roche, Avidia, Boeringer
374 Ingelheim, Rome Therapeutics, Roswell Park, and the Parker Institute for Cancer
375 Immunotherapy. N.B. receives research support from the Parker Insitute, Novocure, Celldex,
376 Genentech, Oncovir, and Regeneron. M.M. serves as an advisor/board member for Celsius,
377 Pionyr, Compugen, Myeloids and Innate pharma and ad hoc for Takeda. M.M. receives research
378 support from Regeneron, Takeda, and Genentech. A.M. has equity in Gilead Sciences and
379 Regeneron Pharmaceuticals.

380 8. Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated
381 exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict
382 severe progression in COVID-19 patients. *Cell Mol Immunol.* 2020;17(5):541-3. Epub
383 2020/03/24. doi: 10.1038/s41423-020-0401-3. PubMed PMID: 32203186; PubMed Central
384 PMCID: PMCPMC7091621.

385 9. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et
386 al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations
387 with Age and Disease Severity. *Cell.* 2020;183(4):996-1012.e19. Epub 2020/10/05. doi:
388 10.1016/j.cell.2020.09.038. PubMed PMID: 33010815; PubMed Central PMCID:
389 PMCPMC7494270.

390 10. Norton KA, Gong C, Jamalian S, Popel AS. Multiscale Agent-Based and Hybrid
391 Modeling of the Tumor Immune Microenvironment. *Processes (Basel).* 2019;7(1). Epub
392 2019/02/01. doi: 10.3390/pr7010037. PubMed PMID: 30701168; PubMed Central PMCID:
393 PMCPMC6349239.

- 394 11. Foy BH, Gonçalves BP, Higgins JM. Unraveling Disease Pathophysiology with
395 Mathematical Modeling. *Annu Rev Pathol.* 2020;15:371-94. Epub 2020/01/25. doi:
396 10.1146/annurev-pathmechdis-012419-032557. PubMed PMID: 31977295.
- 397 12. Zhang C, Qin L, Li K, Wang Q, Zhao Y, Xu B, et al. A Novel Scoring System for
398 Prediction of Disease Severity in COVID-19. *Front Cell Infect Microbiol.* 2020;10:318. Epub
399 2020/06/26. doi: 10.3389/fcimb.2020.00318. PubMed PMID: 32582575; PubMed Central
400 PMCID: PMC7292148.
- 401 13. Cadegiani FA, Zimmerman RA, Campello de Souza B, McCoy J, Pereira ECRA, Gustavo
402 Wambier C, et al. The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt,
403 Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient
404 Cohort. *Cureus.* 2021;13(1):e12565. Epub 2021/01/14. doi: 10.7759/cureus.12565. PubMed
405 PMID: 33437562; PubMed Central PMCID: PMC7793341.
- 406 14. Booth AL, Abels E, McCaffrey P. Development of a prognostic model for mortality in
407 COVID-19 infection using machine learning. *Mod Pathol.* 2020:1-10. Epub 2020/10/18. doi:
408 10.1038/s41379-020-00700-x. PubMed PMID: 33067522; PubMed Central PMCID:
409 PMC7567420.
- 410 15. Ko J, Baldassano SN, Loh PL, Kording K, Litt B, Issadore D. Machine learning to detect
411 signatures of disease in liquid biopsies - a user's guide. *Lab Chip.* 2018;18(3):395-405. Epub
412 2017/12/02. doi: 10.1039/c7lc00955k. PubMed PMID: 29192299; PubMed Central PMCID:
413 PMC5955608.
- 414 16. Pinto BGG, Oliveira AER, Singh Y, Jimenez L, Gonçalves ANA, Ogava RLT, et al.
415 ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with

- 416 Severe COVID-19. medRxiv. 2020. Epub 2020/06/09. doi: 10.1101/2020.03.21.20040261.
417 PubMed PMID: 32511627; PubMed Central PMCID: PMC7276054.
- 418 17. Bonafe M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging:
419 Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine
420 Growth Factor Rev. 2020. Epub 2020/05/12. doi: 10.1016/j.cytogfr.2020.04.005. PubMed
421 PMID: 32389499.
- 422 18. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al.
423 Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med.
424 2020;383(4):334-46. Epub 2020/07/01. doi: 10.1056/NEJMoa2021680. PubMed PMID:
425 32598831; PubMed Central PMCID: PMC7346765.
- 426 19. CDC. COVID-19 in Children and Teens 2020 [10 Jan 2020]. Available from:
427 <https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/children/symptoms.html>.
- 428 20. Afzal A. Molecular diagnostic technologies for COVID-19: Limitations and challenges. J
429 Adv Res. 2020;26:149-59. Epub 2020/08/25. doi: 10.1016/j.jare.2020.08.002. PubMed PMID:
430 32837738; PubMed Central PMCID: PMC7406419.
- 431 21. Ratajczak MZ, Bujko K, Ciechanowicz A, Sielatycka K, Cymer M, Marlicz W, et al.
432 SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45(-) Precursors of
433 Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3
434 Inflammasome. Stem Cell Rev Rep. 2020:1-12. Epub 2020/07/22. doi: 10.1007/s12015-020-
435 10010-z. PubMed PMID: 32691370; PubMed Central PMCID: PMC7370872.
- 436 22. Lukassen SA-O, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. SARS-
437 CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient. Embo J.
438 2020;39(10):e105114 LID - 10.15252/embj.20105114 [doi] LID - e105114.

- 439 23. Hirano T, Murakami M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine
440 Release Syndrome. *Immunity*. 2020;52(5):731-3. Epub 2020/04/24. doi:
441 10.1016/j.immuni.2020.04.003. PubMed PMID: 32325025; PubMed Central PMCID:
442 PMCPMC7175868.
- 443 24. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al.
444 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically. *Cell*.
445 2020;181(2):271-80.e8 LID - S0092-8674(20)30229-4 [pii] LID - 10.1016/j.cell.2020.02.052
446 [doi].
- 447 25. Finkel Y, Mizrahi O, Nachshon A, Weingarten-Gabbay S, Morgenstern D, Yahalom-
448 Ronen Y, et al. The coding capacity of SARS-CoV-2. *Nature*. 2020. Epub 2020/09/10. doi:
449 10.1038/s41586-020-2739-1. PubMed PMID: 32906143.
- 450 26. Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, et al. CD147-spike protein is a
451 novel route for SARS-CoV-2 infection to host cells. *Signal Transduct Target Ther*.
452 2020;5(1):283. Epub 2020/12/06. doi: 10.1038/s41392-020-00426-x. PubMed PMID: 33277466;
453 PubMed Central PMCID: PMCPMC7714896.
- 454 27. Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. Heightened Innate Immune
455 Responses in the Respiratory Tract of COVID-19 Patients. *Cell Host Microbe*. 2020;27(6):883-
456 90.e2. Epub 2020/05/15. doi: 10.1016/j.chom.2020.04.017. PubMed PMID: 32407669; PubMed
457 Central PMCID: PMCPMC7196896.
- 458 28. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of
459 viral load in posterior oropharyngeal saliva samples and serum antibody responses during
460 infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis*. 2020;20(5):565-74.


- 461 Epub 2020/03/28. doi: 10.1016/s1473-3099(20)30196-1. PubMed PMID: 32213337; PubMed
462 Central PMCID: PMCPMC7158907.
- 463 29. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brügger MC, et al.
464 Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-
465 19. *Allergy*. 2020. Epub 2020/05/13. doi: 10.1111/all.14364. PubMed PMID: 32396996;
466 PubMed Central PMCID: PMCPMC7272948.
- 467 30. Catanzaro M, Fagian F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in
468 COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-
469 CoV-2. *Signal Transduction and Targeted Therapy*. 2020;5(1):84. doi: 10.1038/s41392-020-
470 0191-1.
- 471 31. Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, et al. Serum Cytokine and Chemokine
472 Profile in Relation to the Severity of Coronavirus Disease 2019 in China. *J Infect Dis*.
473 2020;222(5):746-54. Epub 2020/06/21. doi: 10.1093/infdis/jiaa363. PubMed PMID: 32563194;
474 PubMed Central PMCID: PMCPMC7337752.
- 475 32. Picchianti Diamanti A, Rosado MM, Pioli C, Sesti G, Laganà B. Cytokine Release
476 Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance
477 between Infections and Autoimmunity. *Int J Mol Sci*. 2020;21(9). Epub 2020/05/14. doi:
478 10.3390/ijms21093330. PubMed PMID: 32397174; PubMed Central PMCID:
479 PMCPMC7247555.
- 480 33. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets
481 of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
482 Unexposed Individuals. *Cell*. 2020;181(7):1489-501.e15. Epub 2020/05/31. doi:





- 483 10.1016/j.cell.2020.05.015. PubMed PMID: 32473127; PubMed Central PMCID:
484 PMCPMC7237901.
- 485 34. Ernst D, Bolton G, Recktenwald D, Cametron MJ, Danesh A, Persad D, et al. Bead Based
486 Flow Cytometric Assays : A Multiplex Assay Platform with Applications in Diagnostic
487 Microbiology. In: Advanced Techniques in Diagnostic Microbiology , Eds : Y.W. Tang and
488 C.W. Stratton. Springer. 2006. p. 427-43.
- 489 35. Bassoli C, Oreni L, Ballone E, Foschi A, Perotti A, Mainini A, et al. Role of serum
490 albumin and proteinuria in patients with SARS-CoV-2 pneumonia. *Int J Clin Pract.*
491 2020:e13946. Epub 2020/12/18. doi: 10.1111/ijcp.13946. PubMed PMID: 33332691.
- 492 36. Payán-Pernía S, Gómez Pérez L, Remacha Sevilla Á F, Sierra Gil J, Novelli Canales S.
493 Absolute Lymphocytes, Ferritin, C-Reactive Protein, and Lactate Dehydrogenase Predict Early
494 Invasive Ventilation in Patients With COVID-19. *Lab Med.* 2020. Epub 2020/12/19. doi:
495 10.1093/labmed/lmaa105. PubMed PMID: 33336243.
- 496 37. Chen Z, John Wherry E. T cell responses in patients with COVID-19. *Nat Rev Immunol.*
497 2020;20(9):529-36. Epub 2020/07/31. doi: 10.1038/s41577-020-0402-6. PubMed PMID:
498 32728222; PubMed Central PMCID: PMC7389156 Roche, Pieris, Elstar and Surface
499 Oncology. E.J.W. has a patent licensing agreement on the PD1 pathway with Roche/Genentech.
500 E.J.W. is a founder of Arsenal Biosciences. Z.C. declares no competing interests.
- 501 38. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust
502 neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science.*
503 2020;370(6521):1227-30. Epub 2020/10/30. doi: 10.1126/science.abd7728. PubMed PMID:
504 33115920.


- 505 39. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment
506 of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest.*
507 2020;130(6):2757-65. Epub 2020/04/08. doi: 10.1172/jci138745. PubMed PMID: 32254064;
508 PubMed Central PMCID: PMC7259988.
- 509 40. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigail J, et al. A longitudinal study of
510 SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and
511 COVID-19 severity. *Cell Mol Immunol.* 2021;18(2):318-27. Epub 2021/01/08. doi:
512 10.1038/s41423-020-00588-2. PubMed PMID: 33408342; PubMed Central PMCID:
513 PMC7786875.
- 514 41. Box G, E., Hunter W, Hunter S. *Statistics for Experimenters: design, discovery and*
515 *innovation*: John Wiley and Sons; 2005.
- 516 42. Piyathilake CJ, Badiga S, Burkholder GA, Harada S, Raper JL. The accuracy of HPV
517 genotyping in isolation and in combination with CD4 and HIV viral load for the identification of
518 HIV-infected women at risk for developing cervical cancer. *Cancer Med.* 2021. Epub
519 2021/02/20. doi: 10.1002/cam4.3785. PubMed PMID: 33605553.
- 520 43. Bland J, Kavanaugh A, Hong LK, Kadkol SS. Development and Validation of Viral Load
521 Assays to Quantitate SARS-CoV-2. *J Virol Methods.* 2021:114100. Epub 2021/02/19. doi:
522 10.1016/j.jviromet.2021.114100. PubMed PMID: 33600849.
- 523 44. Romeo F, Louge Uriarte E, Delgado SG, González-Altamiranda E, Pereyra S, Morán P,
524 et al. Effect of bovine viral diarrhea virus on subsequent infectivity of bovine gammaherpesvirus
525 4 in endometrial cells in primary culture: an in vitro model of viral co-infection. *J Virol Methods.*
526 2021:114097. Epub 2021/02/19. doi: 10.1016/j.jviromet.2021.114097. PubMed PMID:
527 33600847.

- 528 45. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious
529 disease. *Nat Rev Immunol.* 2015;15(2):87-103. Epub 2015/01/24. doi: 10.1038/nri3787. PubMed
530 PMID: 25614319; PubMed Central PMCID: PMC7162685.
- 531 46. Buszko M, Park JH, Verthelyi D, Sen R, Young HA, Rosenberg AS. The dynamic
532 changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. *Nat*
533 *Immunol.* 2020;21(10):1146-51. Epub 2020/08/29. doi: 10.1038/s41590-020-0779-1. PubMed
534 PMID: 32855555.
- 535 47. Cardone M, Yano M, Rosenberg AS, Puig M. Lessons Learned to Date on COVID-19
536 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral
537 Infection and Detrimental Hyperinflammation. *Front Immunol.* 2020;11:1131. Epub 2020/06/24.
538 doi: 10.3389/fimmu.2020.01131. PubMed PMID: 32574265; PubMed Central PMCID:
539 PMC7272717.
- 540 48. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of
541 COVID-19: current state of the science. *Immunity.* 2020. doi: 10.1016/j.immuni.2020.05.002.
542 PubMed PMID: PMC7200337.
- 543 49. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of
544 type I IFN immunity in patients with life-threatening COVID-19. *Science.* 2020;370(6515).
545 Epub 2020/09/26. doi: 10.1126/science.abd4570. PubMed PMID: 32972995.
- 546 50. Rusu D, Blaj M, Ristescu I, Patrascanu E, Gavril L, Lungu O, et al. Outcome Predictive
547 Value of Serum Ferritin in ICU Patients with Long ICU Stay. *Medicina (Kaunas).* 2020;57(1).
548 Epub 2020/12/31. doi: 10.3390/medicina57010001. PubMed PMID: 33375016; PubMed Central
549 PMCID: PMC7822040.

- 550 51. Dahan S, Segal G, Katz I, Hellou T, Tietel M, Bryk G, et al. Ferritin as a Marker of
551 Severity in COVID-19 Patients: A Fatal Correlation. *Isr Med Assoc J.* 2020;22(8):494-500. Epub
552 2020/11/26. PubMed PMID: 33236582.
- 553 52. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-
554 reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science.* 2020;370(6512):89-94.
555 Epub 2020/08/06. doi: 10.1126/science.abd3871. PubMed PMID: 32753554; PubMed Central
556 PMCID: PMC7574914.
- 557 53. Gentili M, Nachohen A. Surprising effects of antibodies in severe COVID. *Nature.* 2021.
- 558 54. Poeschla E. Neutralizing SARS-CoV-2. *Elife.* 2020;9. Epub 2020/12/16. doi:
559 10.7554/eLife.64496. PubMed PMID: 33320086; PubMed Central PMCID: PMC7738179.
- 560 55. Qian, Z. et al. (2013) Innate immune response of human alveolar type II cells infected with
561 severe acute respiratory syndrome-coronavirus. *Am J Respir Cell Mol Biol* 48 (6), 742-8.
- 562 56. Kronbichler, A. et al. (2020) Asymptomatic patients as a source of COVID-19 infections: A
563 systematic review and meta-analysis. *Int J Infect Dis* 98, 180-186. PMID: 32562846;
564 PMCID: PMC7832751; DOI: 10.1016/j.ijid.2020.06.052
- 565 57. Zhao, J. et al. (2020) Antibody responses to SARS-CoV-2 in patients of novel coronavirus
566 disease 2019. LID - 10.1093/cid/ciaa344 [doi] LID - ciaa344. *Clin Infect Dis.*
- 567










Table 1. Ranges of values for the parameters used for developing the simulated dataset for the mathematical model.

| Parameter | Unit | Reference | COVID-19 Ranges | COVID-19 Ranges | COVID-19 Ranges |
|-------------------------------|-------------------------|-----------|-----------------|-----------------|-----------------|
| | | | Asymptomatic | Moderate | Severe |
| Viral Load | Cycle Time | [20] | >28 | 20-15 | 22-16 |
| IFNα | pg/mL | [45, 46] | <10 | 10-100 | 10-2 |
| Fever | °F | [55, 56] | 97-98.6 | 98.6-100 | 100-104 |
| D-Dimer | $\mu\text{g/mL}$ | [31] | <0.1 | 0.15-0.62 | 0.5-9.3 |
| Ferritin | ng/L | [31] | 20-200 | 286-1,275 | 1,400-2,000 |
| Oxygen Saturation | % | [3, 56] | 95-100 | 85-94 | 60-84 |
| IL-6 | ng/mL | [45, 46] | <1 | 19-76 | 19-430 |
| Lymphocyte count | $\times 10^6/\text{mL}$ | [27] | >785 | 588-785 | 169-415 |
| NAB | Titer | [57] | 1,000-45,000 | 200-20,000 | 500-60,000 |

Table 2A. Statistical analysis of coefficients for each parameter based on the multiple regression analysis. The Table shows the regression statistics. The statistical terms are: DF (degrees of freedom); SeqSS (Sequential Sum Square); AdjSS (Adjusted Sum Square), AdjMS (Adjusted Mean Squares), F ratio, p value.

| Source | DF | SeqSS | AjdSS | AdjMS | F | p |
|-------------------------------|----|---------|---------|--------|--------|-------|
| Regression | 11 | 13.172 | 139.172 | 12.652 | 10.259 | 0 |
| AGE | 1 | 116.579 | 0.095 | 0.095 | 0.817 | 0.337 |
| COMORBID | 1 | 10.085 | 0.175 | 0.175 | 1.5 | 0.231 |
| Viral Load | 1 | 0.172 | 0.392 | 0.392 | 3.357 | 0.078 |
| IFNα | 1 | 1.037 | 0.136 | 0.135 | 1.161 | 0.291 |
| Fever | 1 | 8.159 | 0.378 | 0.378 | 3.238 | 0.083 |
| IL6 | 1 | 0.808 | 0.172 | 0.171 | 1.469 | 0.236 |
| D-Dimer | 1 | 1.511 | 0.444 | 0.444 | 3.799 | 0.062 |
| Ferritin | 1 | 0.574 | 0.098 | 0.098 | 0.839 | 0.368 |
| Lymphocyte Count | 1 | 0.018 | 0.039 | 0.039 | 0.334 | 0.568 |
| Oxygen saturation | 1 | 0.91 | 0.133 | 0.133 | 1.141 | 0.295 |
| NAB | 1 | 0.039 | 0.039 | 0.039 | 0.337 | 0.566 |

Table 2B. Coefficient and standard error for parameters. The coefficients for each parameter were determined by using multiple regression analyses, which is the multiplier to the parameter value in a linear regression equation. The values of the coefficients of each of the parameters are shown using ANOVA. The table shows the standard error, t and p values. The p value denotes statistical significance to the outcome.

| Term | Coefficient | Standard Error | t | p |
|--------------------------|--------------------|-----------------------|----------|----------|
| Constant | -36.898 | 24.867 | -1.484 | 0.150 |
| AGE | -0.021 | 0.023 | -0.904 | 0.374 |
| COMORBID | 0.894 | 0.730 | 1.225 | 0.232 |
| Viral Load | -0.048 | 0.026 | -1.832 | 0.078 |
| IFN A | -0.005 | 0.005 | -1.077 | 0.291 |
| Fever | 0.444 | 0.247 | 1.799 | 0.084 |
| IL6 | -0.003 | 0.003 | -1.212 | 0.236 |
| D-Dimer | 0.271 | 0.139 | 1.949 | 0.062 |
| Ferritin | 0.000 | 0.001 | 0.916 | 0.368 |
| Lymphocyte Count | -0.001 | 0.001 | -0.578 | 0.568 |
| Oxygen saturation | -0.038 | 0.036 | -1.068 | 0.295 |
| NAB | 0.000 | 0.000 | -0.580 | 0.567 |
| Error | 26.000 | 3.039 | 3.039 | 0.117 |
| Total | 37.000 | 142.211 | | |

Table 3. The Ranges for the Monte Carlo Simulation.

























| Parameters | Range | | | | Parametric | |
|------------------|-------|---|------|--|-------------|----------------|
| | Max |  | Min |  | | |
| Age | 66 |  | 20 |  | 43 | |
| Comorbidities | 3.6 |  | 1.2 |  | 2.4 | |
| Viral Load | 30 |  | 18 |  | 24 | |
| IFNa | 48 |  | 5 |  | 26.5 | |
| Fever | 104 |  | 97.7 |  | 100.85 | |
| IL6 | 390 |  | 2 |  | 196 | |
| D-Dimer | 6 |  | 0.02 |  | 3.01 | |
| Ferritin | 1775 |  | 30 |  | 902.5 | |
| Lymphocyte Count | 983 |  | 150 |  | 566.5 | |
| O2 saturation | 100 |  | 81 |  | 90.5 | |
| NAB | 1580 |  | 2 |  | 791 | |
| | | | | | 4.50 | Simulated Rank |

Table 4. The Prediction of outcome based on observed and predicted values.

| Variable | Subject 1 | Subject 2 | Subject 3 | Subject 4 | Subject 5 | Subject 6 | Subject 7 |
|-------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Age | 20 | 52 | 55 | 55 | 62 | 73 | 80 |
| Comorbidity | 1.1 | 2.2 | 2.3 | 2.4 | 2.6 | 3.2 | 3.5 |
| Viral Load | 36 | 19 | 16 | 15 | 17 | 21 | 17 |
| IFNa | 7 | 20 | 50 | 60 | 40 | 9 | 5 |
| Fever | 98.6 | 99.1 | 99.8 | 100 | 99.4 | 100.1 | 100 |
| IL6 | 1 | 30 | 60 | 70 | 50 | 50 | 90 |
| D-Dimer | 0.05 | 0.25 | 0.40 | 0.45 | 0.35 | 1.5 | 4.0 |
| Ferritin | 30 | 350 | 800 | 1275 | 500 | 1500 | 1800 |
| Lymphocyte Count | 800 | 740 | 620 | 580 | 640 | 340 | 200 |
| Oxygen Saturation | 100 | 95 | 83 | 85 | 90 | 95 | 94 |
| NAB | 2 | 20 | 150 | 200 | 100 | 220 | 400 |
| Calculated Outcome Rank | 0.723 | 3.299 | 4.008 | 4.237 | 3.228 | 4.916 | 6.427 |
| PREDICTED | 1 | 3 | 4 | 4 | 3 | 5 | 6 |
| OBSERVED | 1 | 3 | 4 | 4 | 4 | 5 | 6 |